Ragheed Saoud, MD
Urology · Riverhead, NYNPI 1093291619
Payments from drug & device makers
Across 32 payments — averaging $230.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avyxa Pharma, LLC$3K
- Conmed Corporation$1K
- Angiodynamics, Inc.$929
- EDAP Technomed Inc$778
- Olympus Corporation Of The Americas$580
- Boston Scientific$130
- plus $149 from 5 others
What the payments were for
- Consulting fees$6359%
- Speaking & faculty fees$2,00027%
- Travel & lodging$3,17743%
- Food & beverage$1,55321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avyxa Pharma, LLC | 5 | $3,314 |
| Conmed Corporation | 5 | $1,484 |
| Angiodynamics, Inc. | 3 | $929 |
| EDAP Technomed Inc | 2 | $778 |
| Olympus Corporation Of The Americas | 10 | $580 |
| Boston Scientific | 2 | $130 |
| Merck | 1 | $45 |
| AstraZeneca | 1 | $43 |
| Endo USA, Inc. | 1 | $23 |
| Teleflex LLC | 1 | $20 |
| Medtronic | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSEAL$1,318
- Nanoknife$929
- FOCAL ONE$778
- Olympus Cystoscopes$473
- Olympus Laser Devices$473
- Olympus Resection Disposables$473
How this compares
$7,365 in reported general payments places this provider in the 70th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 19 | $16,968 |
| Tamsulosin Hcl | 362 | $3,910 |
| Estradiol | 46 | $3,412 |
| Methenamine Hippurate | 39 | $2,552 |
| Finasteride | 196 | $1,977 |
| Oxybutynin Chloride ErOxybutynin Chloride | 103 | $1,746 |
| Oxybutynin Chloride | 134 | $1,054 |
| Solifenacin Succinate | 19 | $1,041 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $807 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 59 | $796 |
| Testosterone Cypionate | 39 | $747 |
| Cephalexin | 32 | $672 |
| Cefpodoxime Proxetil | 11 | $494 |
| Bethanechol Chloride | 11 | $285 |
| Levofloxacin | 61 | $285 |
Paid to pharmacies, not to this prescriber.
Other urology in Riverhead
- Christopher PieczonkaSyracuse$31.2M
- Guarionex DecastroNew York$5.7M
- Mitchell EfrosGarden City$4.2M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Jed KaminetskyMiddle Village$3.5M
- Evan GoldfischerPoughkeepsie$3.1M
- Gennady BratslavskySyracuse$2.5M
- Ashutosh TewariNew York$2.5M
- Manish ViraNew Hyde Park$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.